The pathology of amyloidosis in classification: a review
MM Picken - Acta haematologica, 2020 - karger.com
Background: The amyloidoses are a rare and heterogeneous group of disorders that are
characterized by the deposition of abnormally folded proteins in tissues ultimately leading to …
characterized by the deposition of abnormally folded proteins in tissues ultimately leading to …
AL (light-chain) cardiac amyloidosis: a review of diagnosis and therapy
RH Falk, KM Alexander, R Liao, S Dorbala - Journal of the American …, 2016 - jacc.org
The amyloidoses are a group of protein-folding disorders in which≥ 1 organ is infiltrated by
proteinaceous deposits known as amyloid. The deposits are derived from 1 of several …
proteinaceous deposits known as amyloid. The deposits are derived from 1 of several …
Pathophysiology and therapeutic approaches to cardiac amyloidosis
JM Griffin, H Rosenblum, MS Maurer - Circulation research, 2021 - Am Heart Assoc
Often considered a rare disease, cardiac amyloidosis is increasingly recognized by
practicing clinicians. The increased rate of diagnosis is in part due the aging of the …
practicing clinicians. The increased rate of diagnosis is in part due the aging of the …
Cardiac amyloidosis: pathology, nomenclature, and typing
JJ Maleszewski - Cardiovascular Pathology, 2015 - Elsevier
Amyloidosis is an increasingly recognized cause of heart disease, caused by the deposition
of misfolded protein within the heart. These proteins may deposit systemically and include …
of misfolded protein within the heart. These proteins may deposit systemically and include …
Neoplasia and the heart: pathological review of effects with clinical and radiological correlation
JJ Maleszewski, MC Bois, JP Bois, PM Young… - Journal of the American …, 2018 - jacc.org
The intersection of oncological and cardiovascular diseases is an increasingly recognized
phenomenon. This recognition has led to the emergence of cardio-oncology as a true …
phenomenon. This recognition has led to the emergence of cardio-oncology as a true …
Molecular mechanisms of cardiac amyloidosis
Y Saito, K Nakamura, H Ito - International journal of molecular sciences, 2021 - mdpi.com
Cardiac involvement has a profound effect on the prognosis of patients with systemic
amyloidosis. Therapeutic methods for suppressing the production of causative proteins have …
amyloidosis. Therapeutic methods for suppressing the production of causative proteins have …
Secondary, AA, amyloidosis
R Papa, HJ Lachmann - Rheumatic Disease Clinics, 2018 - rheumatic.theclinics.com
Secondary, AA, amyloidosis is a rare systemic complication that can develop in any long-
term inflammatory disorder, characterized by the pathogenic extracellular deposition of …
term inflammatory disorder, characterized by the pathogenic extracellular deposition of …
Amyloidosis: insights from proteomics
A Dogan - Annual Review of Pathology: Mechanisms of Disease, 2017 - annualreviews.org
Amyloidoses are a spectrum of disorders caused by abnormal folding and extracellular
deposition of proteins. The deposits lead to tissue damage and organ dysfunction …
deposition of proteins. The deposits lead to tissue damage and organ dysfunction …
Cardiac amyloid load: a prognostic and predictive biomarker in patients with light-chain amyloidosis
AV Kristen, E Brokbals, F aus dem Siepen… - Journal of the American …, 2016 - jacc.org
Background: Cardiac amyloid load has not been analyzed for its effect on mortality in
patients with amyloid light-chain (AL) cardiac amyloidosis. Objectives: This study …
patients with amyloid light-chain (AL) cardiac amyloidosis. Objectives: This study …
Incidence and characterization of concealed cardiac amyloidosis among unselected elderly patients undergoing post-mortem examination
A Porcari, R Bussani, M Merlo, GG Varrà… - Frontiers in …, 2021 - frontiersin.org
Background: The prevalence of cardiac amyloidosis (CA) is unknown. Aims and Methods:
We sought to (a) determine the prevalence of CA in unselected patients≥ 75 years …
We sought to (a) determine the prevalence of CA in unselected patients≥ 75 years …